Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee.
Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee.
Pediatr Blood Cancer. 2019 Jul;66(7):e27750. doi: 10.1002/pbc.27750. Epub 2019 Apr 16.
There is mounting evidence that combination of antibiotic therapy with vancomycin and piperacillin/tazobactam (pip/tazo) is associated with acute kidney injury (AKI). To determine whether vancomycin plus pip/tazo is associated with higher rates of AKI compared to vancomycin plus cefepime among pediatric hematology/oncology (heme/onc) patients, we examined 121 heme/onc patients receiving at least two consecutive days of therapy with vancomycin and either pip/tazo or cefepime. Rate of AKI was higher in the pip/tazo than the cefepime group (4/27 [14.8%] vs 2/94 [2.1%], P = 0.022).
越来越多的证据表明，将抗生素治疗与万古霉素和哌拉西林/他唑巴坦（哌拉西林/他唑巴坦）联合使用与急性肾损伤（AKI）有关。为了确定万古霉素联合哌拉西林/他唑巴坦与万古霉素联合头孢吡肟相比，在儿科血液科/肿瘤科（血液科/肿瘤科）患者中是否与更高的 AKI 发生率相关，我们检查了 121 名接受至少连续两天万古霉素治疗的血液科/肿瘤科患者，这些患者使用的药物为哌拉西林/他唑巴坦或头孢吡肟。哌拉西林/他唑巴坦组的 AKI 发生率高于头孢吡肟组（4/27 [14.8%] vs 2/94 [2.1%]，P = 0.022）。
